Shattuck Labs (STTK) Stock Price, News & Analysis

-0.28 (-2.92%)
(As of 04/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
307,185 shs
Average Volume
365,119 shs
Market Capitalization
$441.47 million
P/E Ratio
Dividend Yield
Price Target

Shattuck Labs MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
115.1% Upside
$20.00 Price Target
Short Interest
4.40% of Float Sold Short
Dividend Strength
News Sentiment
-0.13mentions of Shattuck Labs in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$168,522 Sold Last Quarter
Proj. Earnings Growth
From ($1.85) to ($1.93) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.10 out of 5 stars

Medical Sector

776th out of 909 stocks

Pharmaceutical Preparations Industry

363rd out of 426 stocks

STTK stock logo

About Shattuck Labs Stock (NASDAQ:STTK)

Shattuck Labs, Inc., is a clinical-stage biotechnology company that is revolutionizing the field of cancer and autoimmune disease therapeutics. Founded in 2016, Shattuck Labs set out with a mission to develop novel treatments that address significant unmet medical needs. The company's innovative approach centers around bi-functional fusion proteins derived from its proprietary Agonist Redirected Checkpoint (ARC) platform technology.

The ARC platform developed by Shattuck Labs is a groundbreaking scientific advancement. It enables the simultaneous inhibition of checkpoint molecules and activation of costimulatory molecules within a single therapeutic compound. This unique mechanism of action holds immense promise for enhancing the efficacy of cancer and autoimmune disease treatments. Shattuck Labs' lead program, SL-172154 (SIRPα-Fc-CD40L), exemplifies the power of the ARC platform. SL-172154 targets the CD47 immune checkpoint while activating the CD40 receptor, a tumor necrosis factor superfamily member. The compound is currently being evaluated in multiple Phase 1 clinical trials, with promising early results.

Shattuck Labs is committed to developing transformational medicines that significantly improve patients' lives. The company's target market encompasses individuals with cancer and autoimmune diseases who face high unmet medical needs. By addressing these critical areas, Shattuck Labs aims to profoundly impact patients' lives worldwide.

Shattuck Labs is led by a dynamic and experienced management team that drives the company's vision and execution. At the helm is Dr. Taylor H. Schreiber, co-founder and Chief Executive Officer, whose scientific expertise and strategic vision have been instrumental in the company's success. Dr. Schreiber is joined by a talented group of executives, including Dr. Abhinav A. Shukla as Chief Technical Officer, Dr. Arundathy Nirmalini Pandite as Chief Medical Officer, and Mr. Andrew R. Neill as Chief Financial Officer. Each leadership team member brings a wealth of experience and expertise, ensuring the company's continued growth and innovation.

Shattuck Labs has demonstrated financial progress. The company has grown over recent years, reflecting the increasing demand for innovative therapies. While focusing on research and development, Shattuck Labs has diligently managed costs and improved its profit margins, showcasing financial discipline and operational efficiency. These positive trends highlight the company's ability to execute its business strategy effectively.

Shattuck Labs' valuation metrics illustrate its potential for growth and attractiveness to investors. The uniqueness of its ARC platform and the promising pipeline of bi-functional fusion proteins contribute to its valuation. As the company achieves significant milestones, such as positive clinical trial results and regulatory advancements, investor sentiment is positively influenced. Shattuck Labs' valuation is often benchmarked against industry peers, providing further insights into its growth potential and market positioning.

Shattuck Labs' stock performance on NASDAQ is subject to various factors, including market conditions and news related to clinical trials and commercialization prospects. Positive clinical trial results, regulatory milestones, and successful collaborations can positively impact the company's share price. Conversely, setbacks or negative news may result in short-term fluctuations. When evaluating the company's market performance, investors must consider the long-term potential of Shattuck Labs' innovative therapies.

Shattuck Labs operates in the highly competitive pharmaceutical preparations industry. The company stands out within this industry due to its unique ARC platform, which sets it apart from traditional therapeutic approaches. The ability to simultaneously inhibit checkpoint molecules and activate costimulatory molecules provides a distinct advantage in developing more effective treatments. Shattuck Labs' competitive positioning is further strengthened by its strong scientific foundation, strategic collaborations, and focus on transformative therapies.

Shattuck Labs is well-positioned to capitalize on several growth opportunities. The company's innovative ARC platform and pipeline of bi-functional fusion proteins offer significant potential for addressing unmet medical needs in cancer and autoimmune diseases. By leveraging its expertise and scientific excellence, Shattuck Labs can continue to advance its therapies through clinical development and potentially bring life-changing treatments to patients worldwide. Strategic partnerships and collaborations are also key growth drivers for the company.

As with any biotechnology company, Shattuck Labs faces inherent risks and challenges. These include the complexities of the clinical development process, regulatory requirements, and the need for substantial investment in research and development. Managing these risks requires a robust risk management strategy, including close collaboration with regulatory authorities, rigorous scientific research, and continuous evaluation of potential mitigating factors. Shattuck Labs is committed to navigating these challenges to ensure its therapies' successful development and commercialization.

STTK Stock Price History

STTK Stock News Headlines

STTK May 2024 7.500 call
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
STTK Apr 2024 17.500 call
STTK Apr 2024 7.500 put
Shattuck Labs (STTK) Receives a Buy from TD Cowen
STTK Mar 2024 17.500 call
STTK Mar 2024 5.000 put
STTK Mar 2024 10.000 call
STTK Mar 2024 10.000 put
See More Headlines
Receive STTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shattuck Labs and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$1.66 million
Book Value
$3.41 per share


Free Float
Market Cap
$441.47 million
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Taylor H. Schreiber M.D. (Age 44)
    Ph.D., Co-Founder, CEO & Director
    Comp: $783.75k
  • Dr. Abhinav A. Shukla Ph.D. (Age 51)
    Chief Technical Officer
    Comp: $567.4k
  • Dr. Arundathy Nirmalini Pandite M.B.A. (Age 64)
    M.D., Chief Medical Officer
    Comp: $678.76k
  • Mr. Andrew R. Neill M.B.A.Mr. Andrew R. Neill M.B.A. (Age 38)
    Chief Financial Officer
  • Mr. Conor Richardson CPA
    Vice President of Investor Relations
  • Dr. Stephen Stout J.D.
    Ph.D., General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer
  • Ms. Casi DeYoung (Age 53)
    Chief Business Officer
    Comp: $523.48k
  • Dr. Thomas Lampkin Pharm.D.
    Senior Vice President of Regulatory Affairs
  • Mr. George Fromm Ph.D.
    Chief Scientific Officer of ARC Platform
  • Mr. Suresh de Silva Ph.D.
    Chief Scientific Officer of GADLEN Platform

STTK Stock Analysis - Frequently Asked Questions

Should I buy or sell Shattuck Labs stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Shattuck Labs in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STTK shares.
View STTK analyst ratings
or view top-rated stocks.

What is Shattuck Labs' stock price target for 2024?

2 brokerages have issued 12-month price targets for Shattuck Labs' shares. Their STTK share price targets range from $12.00 to $28.00. On average, they predict the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 115.1% from the stock's current price.
View analysts price targets for STTK
or view top-rated stocks among Wall Street analysts.

How have STTK shares performed in 2024?

Shattuck Labs' stock was trading at $7.13 at the start of the year. Since then, STTK shares have increased by 30.4% and is now trading at $9.30.
View the best growth stocks for 2024 here

When is Shattuck Labs' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our STTK earnings forecast

How were Shattuck Labs' earnings last quarter?

Shattuck Labs, Inc. (NASDAQ:STTK) announced its earnings results on Thursday, February, 29th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.10. The business earned $0.71 million during the quarter, compared to analyst estimates of $0.50 million. Shattuck Labs had a negative trailing twelve-month return on equity of 63.08% and a negative net margin of 5,268.44%.

When did Shattuck Labs IPO?

Shattuck Labs (STTK) raised $150 million in an IPO on Friday, October 9th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Evercore ISI acted as the underwriters for the IPO and Needham & Co. was co-manager.

Who are Shattuck Labs' major shareholders?

Shattuck Labs' stock is owned by a variety of institutional and retail investors. Top institutional investors include Cannon Global Investment Management LLC (0.02%). Insiders that own company stock include Andrew R Neill, Erin Ator Thomson, George Golumbeski, Josiah Hornblower, Stephen Stout, Taylor Schreiber and Tyler Brous.
View institutional ownership trends

How do I buy shares of Shattuck Labs?

Shares of STTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:STTK) was last updated on 4/22/2024 by Staff

From Our Partners